Alpha Cognition Inc. (ACOG): Revenue

Annual figures by period end, from SEC filings.

$10.22M

Year ended 2025-12-31

$15.26M

Trailing 12 months to 2026-06-30

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$10.22M	n/a	2026-03-31, From 2025-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Alpha Cognition Inc. (ACOG)	2025-12-31	$10.22M	n/a
TScan Therapeutics, Inc. (TCRX)	2025-12-31	$10.32M	+266.7%
Taysha Gene Therapies, Inc. (TSHA)	2025-12-31	$9.77M	+17.3%
Curis Inc (CRIS)	2025-12-31	$9.44M	-13.4%
Caribou Biosciences, Inc. (CRBU)	2025-12-31	$11.16M	+11.7%
Lineage Cell Therapeutics, Inc. (LCTX)	2025-12-31	$14.56M	+53.2%
Relay Therapeutics, Inc. (RLAY)	2025-12-31	$15.36M	+53.4%
Fate Therapeutics Inc (FATE)	2025-12-31	$6.65M	-51.2%
Pelthos Therapeutics Inc. (PTHS)	2025-12-31	$16.80M	n/a

Compare ACOG, TCRX, TSHA, CRIS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗